Metraipolis › archive › dc_8ce089dda059
Synergistic antitumor activity of sorafenib and the NUPR1 inhibitor LZX-2-73 in multiple cancer models — Europe PMC PMID:41249113
- Source
- Europe PMC (en)
- Original
- https://europepmc.org/article/MED/41249113
- DOI
- 10.1038/s41419-[numero omesso]-8
- License (as archived)
- solo-consultazione
- Archived
- 2026-11-08T12:36:45.458Z
- SHA-256 of the archived text
74dda4bc2189c19fd2ad2bd202b1cccfc57e1458fe7d3b9853e57fd7adbe2fc7- Stable URL of this page
https://metraipolis.com/documento/dc_8ce089dda059
How to cite
Synergistic antitumor activity of sorafenib and the NUPR1 inhibitor LZX-2-73 in multiple cancer models — Europe PMC PMID:41249113 — Europe PMC (en), https://europepmc.org/article/MED/41249113 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_8ce089dda059 (Metraipolis archive dc_8ce089dda059, sha256 74dda4bc2189c19fd2ad2bd202b1cccfc57e1458fe7d3b9853e57fd7adbe2fc7)
BibTeX
@misc{dc8ce089dda059,
title = {Synergistic antitumor activity of sorafenib and the NUPR1 inhibitor LZX-2-73 in multiple cancer models — Europe PMC PMID:41249113},
howpublished = {Europe PMC (en)},
url = {https://europepmc.org/article/MED/41249113},
note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_8ce089dda059; sha256 74dda4bc2189c19fd2ad2bd202b1cccfc57e1458fe7d3b9853e57fd7adbe2fc7},
year = {2026}
}Archived text
The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41249113. Agents can read the archived copy with the MCP tool read_document.